INBRX-103 is a monoclonal antibody that targets cluster of differentiation 47 (CD47) on the surface of tumor cells. CD47 is co-opted by many tumors to protect cancer cells from being engulfed by macrophages, white blood cells that have the ability to locate and “eat” infectious agents. Despite promising activity, anti-CD47 antibody therapeutics are known to cause anemia and infusion site reactions. To our knowledge, INBRX-103 was the first anti-CD47 antibody to block the interaction of CD47 and signal regulatory protein alpha, or SIRPα, without causing the agglutination, or clumping, of red blood cells. In preclinical studies, INBRX-103 had a favorable toxicity profile in nonhuman primates and was not associated with red blood cell or platelet depletion. We believe this lack of red blood cell agglutination may result in a differentiated clinical profile with minimal anemia and a decreased probability of infusion site reactions. We believe this program has broad therapeutic potential in combination with tumor-targeting antibodies that can engage activating Fc receptors, which are found on the surface of phagocytic cells and may further enhance the impact of blocking CD47. In 2012, the worldwide development and commercialization rights to INBRX-103 were licensed to Celgene Corporation. Celgene is currently conducting a Phase 1 clinical trial of this therapeutic candidate in combination with Rituxan® under the name CC-90002.